The global TB Diagnostic market size is USD 2251.6 million in 2024.

According to Cognitive Market Research, the global TB Diagnostic market size will be USD 2251.6 million in 2024. It will expand at a compound annual growth rate (CAGR) of 6.00% from 2024 to 2031.North America held the major market share for more than 40% of the global revenue with a market size of USD 900.64 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.2% from 2024 to 2031.Europe accounted for a market share of over 30% of the global revenue with a market size of USD 675.48 million.Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 517.87 million in 2024 and will grow at a compound annual growth rate (CAGR) of 8.0% from 2024 to 2031.Latin America had a market share of more than 5% of the global revenue with a market size of USD 112.58 million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.4% from 2024 to 2031.Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 45.03 million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.7% from 2024 to 2031.The Diagnostic Laboratories held the highest TB Diagnostic market revenue share in 2024.  Market Dynamics of TB Diagnostic MarketKey Drivers for TB Diagnostic MarketRising Prevalence of TB to Increase the Demand GloballyMycobacterium tuberculosis is the microorganism that causes tuberculosis. Despite being curable, HPV remains one of the top causes of mortality for adults, particularly in underdeveloped countries. According to estimates from the World Health Organization (WHO), approximately 25% of people worldwide suffer from tuberculosis. It means that although a person has been exposed to the tuberculosis germs, they are not ill and hence cannot spread the illness. Additionally, those with tuberculosis have a 5% to 10% probability of developing a serious illness. Individuals with compromised immune systems, like those with HIV, diabetes, malnourishment, or tobacco use, are at a heightened risk of illness. In the world, tuberculosis ranks thirteenth in terms of cause of death and is the second-leading infectious killer, behind COVID-19, just below HIV/AIDS. 1.5million people died from tuberculosis in 2020, including 214000 people with HIV. Source: https://www.who.int/news-room/fact-sheets/detail/tuberculosis Growing Collaboration to Propel Market GrowthThe growing collaboration is expected to offer a lucrative opportunity for market expansion during the projected period. For instance, in March 2023, the United States Agency for International Development (USAID), the Stop TB Partnership, and the Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) have announced a new partnership with Molbio Diagnostics that will ensure prompt service and maintenance of diagnostic instruments and significantly lower the cost of the Truenat® MTB and MTB Plus tests. The partnership will also supply MTB-RIF Dx tests for follow-up testing for rifampicin resistance. Through this agreement, underserved communities in all countries supported by the Stop TB Partnership, USAID, and the Global Fund will have equitable access to high-quality fast testing.Restraint Factor for the TB Diagnostic MarketTechnical Limitation to Limit the SalesAlthough better diagnostic technologies for tuberculosis are critically needed and becoming more so, there are a few obstacles that could hinder market expansion in the next years. For instance, certain technical issues with tuberculosis diagnostics may be a significant barrier to market revenue growth. Furthermore, one of the main factors preventing the market's revenue from growing faster is the greater technical difficulty involved in creating these diagnostic technologies. The most common diagnostic test for tuberculosis, for example, is sputum smear microscopy, albeit it has drawbacks like low sensitivity. Additionally, this could lead to false positive results in people with HIV infection, the elderly, and children. Furthermore, it cannot be utilized to rule out tuberculosis extrapulmonary.Impact of Covid-19 on the TB Diagnostic MarketThe COVID-19 pandemic has affected several facets of tuberculosis detection and treatment, including the market for tuberculosis diagnostics. The pandemic has made people more conscious of how crucial quick and precise diagnoses are. As a result, there h...

据认知市场研究，全球结核病诊断市场规模预计在2024年将达到22.51亿美元。从2024年至2031年，该市场规模将以6.00%的复合年增长率（CAGR）扩张。北美在全球收入中占据了超过40%的主要市场份额，2024年的市场规模为9.0064亿美元，并将在2024年至2031年期间以4.2%的复合年增长率（CAGR）增长。欧洲在全球收入中占据了超过30%的市场份额，市场规模为6.7548亿美元。亚太地区在全球收入中占据了约23%的市场份额，2024年的市场规模为5.1787亿美元，并将在2024年至2031年期间以8.0%的复合年增长率（CAGR）增长。拉丁美洲在全球收入中占据了超过5%的市场份额，2024年的市场规模为1.1258亿美元，并将在2024年至2031年期间以5.4%的复合年增长率（CAGR）增长。中东和非洲在全球收入中占据了约2%的市场份额，2024年的市场规模估计为4.503亿美元，并将在2024年至2031年期间以5.7%的复合年增长率（CAGR）增长。2024年，诊断实验室占据了结核病诊断市场最高收入份额。
结核病诊断市场动态
结核病诊断市场的主要驱动因素
全球结核病患病率的上升将增加全球需求
结核分枝杆菌是引起结核病的微生物。尽管可治愈，但结核病仍然是成年人，尤其是在欠发达国家的首要死亡原因之一。根据世界卫生组织（WHO）的估计，全球约有25%的人患有结核病。这意味着尽管一个人接触了结核菌，但他们并未患病，因此无法传播疾病。此外，患有结核病的人有5%至10%的概率发展为严重疾病。免疫系统受损的人群，如HIV、糖尿病、营养不良或吸烟者，面临更高的患病风险。在全球范围内，结核病在死亡原因中排名第13位，是仅次于COVID-19、HIV/AIDS的第二大传染杀手。2020年，有150万人死于结核病，其中包括21.4万人感染了HIV。
随着合作的增长，推动市场增长
随着合作的增长，预计将在预测期内为市场扩张提供有利可图的机遇。例如，2023年3月，美国国际开发署（USAID）、终止结核病伙伴关系以及全球抗击艾滋病、结核病和疟疾基金（全球基金）宣布与Molbio Diagnostics建立新的合作伙伴关系，以确保诊断仪器的及时服务和维护，并显著降低Truenat® MTB和MTB Plus测试的成本。该伙伴关系还将提供MTB-RIF Dx测试，用于对利福平耐药性进行后续检测。通过这项协议，所有由终止结核病伙伴关系、USAID和全球基金支持的国家中的弱势群体将能够公平地获得高质量的快速检测。
结核病诊断市场的制约因素
技术限制将限制销售额
尽管迫切需要更好的结核病诊断技术，并且这种需求正在日益增长，但仍有一些障碍可能会阻碍未来几年的市场扩张。例如，某些结核病诊断技术中存在的技术问题可能成为市场收入增长的重大障碍。此外，阻碍市场收入更快增长的主要因素之一是创建这些诊断技术所涉及的技术难度更大。例如，结核病的最常见诊断测试是痰涂片显微镜检查，尽管它存在敏感性低等缺点。此外，这可能导致HIV感染者、老年人和儿童出现假阳性结果。此外，它不能用于排除肺外结核病。
COVID-19对结核病诊断市场的影响
COVID-19大流行影响了结核病检测和治疗的多方面，包括结核病诊断市场。大流行使人们更加意识到快速和精确诊断的重要性。因此，这导致了对高质量快速检测的需求增加。